Advertisement
Nivolumab, CV301 and systemic chemotherapy trial
Treatment based on next generation sequencing shows promise
New drug among the most potent antibody-drug conjugates in development
During global health crisis, investigational drug proves successful
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
IMbrave-150 changes standard of care
Selpercatinib beats others in ORR, PFS, safety
Add prophylaxis for patients receiving systemic therapy
Analysis provides evidence to guide treatment of uncommon RCC subtypes
Immunotherapy, PARP inhibitors and a targeted therapy
Results of two studies presented at 2019 ASCO GU
Advertisement
Advertisement